Lyophilized Symbiotic Mitigates Mucositis Induced by 5-Fluorouracil

Savassi, Bruna; Cordeiro, Bárbara Fernandes; Silva, Sara; Oliveira, Emiliano R.; Belo, Giovanna A.; Figueiroa, Alessandra; Queiroz, Maria Izabel Alves; Faria, Ana Maria Caetano; Alves, Juliana Dias; Silva, Tales Fernando da; Campos, Gabriela Munis; Esmerino, Erick A.; Rocha, Ramon S.; Freitas, Mônica Q.; Silva, Márcia; Cruz, Adriano G.; Vital, Kátia Duarte; Fernandes, Simone Odília Antunes; Cardoso, Valbert Nascimento; Acúrcio, Leonardo Borges; Loir, Yves Le; Gala-García, Alfonso; Carmo, Fillipe Luiz Rosa Do

doi:10.3389/fphar.2021.755871

Cited by 10 publications

(8 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To assess and compare their health effects, CEC15 and EcN strains were also tested in a mice 5-FU mucositis model. The reason for selecting this model is its high severity, which would enable the observation of notable protective effects promoted by any potential probiotic strains [4,104,105] and the fact that it is a well-established model [106][107][108][109][110]. Furthermore, it is crucial to emphasize the absence of studies assessing the impact of both EcN and CEC15 on the 5-FU-induced intestinal mucositis model, with the exception of two studies evaluating the effects of EcN supernatant [111,112].…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Probiogenomics Analysis of the Commensal Escherichia Coli CEC15 as a Potential Probiotic Strain

Silva

Glória

Sousa

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Probiotics have gained attention for their potential maintaining gut and immune homeostasis. They have been found to confer protection against pathogen colonization, possess immunomodulatory effects, enhance gut barrier functionality, and mitigate inflammation. However, a thorough understanding of the unique mechanisms of effects triggered by individual strains is necessary to optimize their therapeutic efficacy. Probiogenomics, involving high-throughput techniques, can help identify uncharacterized strains and aid in the rational selection of new probiotics. This study evaluates the potential of the Escherichia coli CEC15 strain as a probiotic through in silico, in vitro, and in vivo analyses, comparing it to the reference E. coli Nissle 1917. Genomic analysis was conducted to identify traits with potential beneficial activity and to assess the safety of each strain (genomic islands, bacteriocin production, antibiotic resistance, production of proteins involved in host homeostasis, and proteins with adhesive properties). In vitro studies assessed survival in gastrointestinal simulated conditions and adhesion to cultured human intestinal cells. Safety was evaluated in BALB/c mice, monitoring the impact of E. coliconsumption on clinical signs, intestinal architecture, intestinal permeability, and fecal microbiota. Additionally, the protective effects of both strains were assessed in a murine model of 5-FU-induced mucositis. Results:CEC15 mitigates inflammation, reinforces intestinal barrier and modulates intestinal microbiota. In silico analysis revealed fewer pathogenicity-related traits in CEC15, when compared to Nissle 1917, with fewer toxin-associated genes and no gene suggesting the production of colibactin (a genotoxic agent). The majority of predicted antibiotic-resistance genes were neither associated with actual resistance, nor with transposable elements. The genome of CEC15 strain encodes proteins related to stress tolerance and to adhesion, in line with its better survival during digestion and higher adhesion to intestinal cells, when compared to Nissle 1917. Moreover, CEC15 exhibited beneficial effects on mice and its intestinal microbiota, both in healthy animals and against 5FU-induced intestinal mucositis. Conclusions: These findings suggest that the CEC15 strain holds promise as a probiotic, capable of modulating the intestinal microbiota, providing immunomodulatory and anti-inflammatory effects, and reinforcing the intestinal barrier. These findings may have implications for the treatment of gastrointestinal disorders, particularly inflammatory bowel disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Comprehensive Probiogenomics Analysis of the Commensal Escherichia Coli CEC15 as a Potential Probiotic Strain

Silva

Glória

Sousa

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Кроме эффективной противоопухолевой активности 5-фторурацил обладает множеством побоч-ных действий, которым подвержены система кроветворения, печень, кожа, нервные клетки, сердечно-сосудистая и мочевыделительная системы. Но чаще всего страдает слизистая оболочка желудка и кишечника [12][13][14]. При применении 5-фторурацила частота развития данных нежелательных явлений со стороны желудочно-кишечного тракта составляет около 30-40 % [12].…”

Section: результаты и обсуждениеunclassified

“…Воспаление слизистой оболочки желудка и двенадцатиперстной кишки, возникающее вследствие проведения химиотерапии, называется мукозитом [12,14,15]. В патогенезе его возникновения и развития выделяют несколько фаз.…”

Section: результаты и обсуждениеunclassified

Erosive-ulcerative lesions of the mucous membrane of the stomach and duodenum during therapy with 5-fluorouracil

Yakimenko

Kutukov

Antonyan

et al. 2022

jour

View full text Add to dashboard Cite

Introduction. Adjuvant therapy with the inclusion of 5-fluorouracil is used in patients with neoplasms of the colon and rectosigmoid in the postoperative period. However, along with a positive antitumor effect, 5-fluorouracilcontaining regimens have a negative effect on the mucosa of the gastrointestinal tract, which often leads to the need to replace or cancel drugs, thereby reducing the effectiveness of treatment.Aim of the study was to improve the idea of the possibility of erosive and ulcerative lesions of the stomach and duodenum during treatment with 5-fluorouracil in patients with malignant tumors of the colon and rectosigmoid and the factors that aggravate their course, as well as to highlight the problem of prevention and treatment of gastrointestinal complications.Materials and methods The search for publications by keywords was carried out in the databases of PubMed, Google Scholar, elibrary.ru and Russian specialized journals related to therapy, surgery, gastroenterology, oncology for the period from 2010 to 2022.Results and Discussion An analysis of the literature allows us to conclude that the risk of damage to the mucous membrane of the stomach and duodenum during the use of chemotherapy with the inclusion of 5-fluorouracil is very high and amounts to 30–40 %. In addition, there are many factors that can complicate the course of this undesirable phenomenon. These include the advanced age of patients, the presence of serious comorbidity and postoperative complications in patients, as well as infection with Helicobacter pylori. The lack of generally accepted recommendations for the prevention and treatment of damage to the lining of the stomach and duodenum during the use of chemotherapy is a serious problem in modern medical practice.Conclusion Gastrointestinal toxicity associated with the use of 5-fluorouracil in the form of mucositis in patients with malignant neoplasms of the colon and rectosigmoid deserves close attention. The presence of damage to the mucous membrane of the stomach and duodenum in a patient requires immediate therapy, as this will improve the long-term results of the treatment of the underlying disease and ensure a high quality of life for the patient.

show abstract

“…Кроме эффективной противоопухолевой активности 5-фторурацил обладает множеством побочных действий, которым подвержены система кроветворения, печень, кожа, нервные клетки, сердечно-сосудистая и мочевыделительная системы. Но чаще всего страдает слизистая оболочка желудка и кишечника [12,13,14]. При применении 5-фторурацила частота развития данных нежелательных явлений со стороны желудочно-кишечного тракта составляет около 30-40% [12].…”

unclassified

“…При применении 5-фторурацила частота развития данных нежелательных явлений со стороны желудочно-кишечного тракта составляет около 30-40% [12]. Воспаление слизистой оболочки желудка и двенадцатиперстной кишки, возникающее вследствие проведения химиотерапии, называется мукозитом [12,14,15,16].…”

unclassified

Профилактика Гастроинтестинальных Нежелательных Явлений Во Время Терапии 5-Фторурацилом

Кутуков¹,

Антонян²,

Якименко³

et al. 2022

Профилактика Гастроинтестинальных Нежелательных Явлений Во Время Терапии 5-Фторурацилом

View full text Add to dashboard Cite

Gastrointestinal toxicity arising from the use of 5-fluorouracil in the form of mucositis in patients with malignant neoplasms of the colon and rectosigmoid deserves close attention. An analysis of the literature allows us to conclude that the risk of damage to the mucous membrane of the stomach and duodenum during the use of chemotherapy with the inclusion of 5-fluorouracil is very high and amounts to 30-40%. In addition, there are many factors that can complicate the course of this undesirable phenomenon. These include the advanced age of patients, the presence of serious comorbidity and postoperative complications in patients, as well as infection with Helicobacter pylori. The lack of generally accepted recommendations for the prevention and treatment of damage to the lining of the stomach and duodenum during the use of chemotherapy is a serious problem in modern medical practice.

show abstract

Lyophilized Symbiotic Mitigates Mucositis Induced by 5-Fluorouracil

Cited by 10 publications

References 45 publications

Comprehensive Probiogenomics Analysis of the Commensal Escherichia Coli CEC15 as a Potential Probiotic Strain

Comprehensive Probiogenomics Analysis of the Commensal Escherichia Coli CEC15 as a Potential Probiotic Strain

Erosive-ulcerative lesions of the mucous membrane of the stomach and duodenum during therapy with 5-fluorouracil

Профилактика Гастроинтестинальных Нежелательных Явлений Во Время Терапии 5-Фторурацилом

Contact Info

Product

Resources

About